SCIEX and Hepregen Announce Co-Marketing Agreement
News May 22, 2015
SCIEX and Hepregen Corporation have announced a Co-Marketing Agreement to deliver a new metabolite identification (Met ID) solution for drug metabolism scientists. From cell culture to interpretation, this solution provides an extensive view into in vitro data to enable researchers to generate, identify and analyze metabolites in one simple workflow. Customers are guided through the entire workflow, including report generation, with an easy-to-use software solution from start to finish.
This Met ID solution mitigates the chances of downstream drug failure for customers, resulting in higher success rates for drug candidate selection, ensuring that an important metabolite will not be missed.
This Comprehensive Met ID solution includes:
• HepatoPac®: Generates at least 25-30% more metabolites for all drug-development relevant species using in vitro hepatocyte assay
• SWATH® Acquisition: Provides increased capability to capture all data with one injection
• TripleTOF® 6600 LC-MS System: Increases accuracy, speed, and dynamic range for quan-qual workflows
• MetabolitePilot™ Software: Parses data and easily produces reports based on research goals
These combined best-in-class tools and methods offer this complete in vitro metabolite identification, profiling and stability solution, using only micromolar to sub-micromolar amounts of new chemical entities. Drug metabolism scientists can now easily detect potentially reactive, toxic, active, and inactive metabolites at trace levels, with high confidence, and unprecedented speed.
“Until now, particularly in the case of low-turnover compounds, drug metabolism researchers have had significant difficulty predicting in vitro metabolic outcomes with complete confidence, said Joe Fox, Senior Director of Pharma Business at SCIEX. “Together with Hepregen, we have established this much needed end-to-end solution for our Met ID customers by combining our best-in-class TripleTOF MS instruments, SWATH Acquisition and MetabolitePilot software with HepatoPac kits for the species most relevant for drug development.”
“By combining the proven and comprehensive metabolite-generating capability of Hepregen HepatoPac® kits with the best-in-class SCIEX LC-MS solution, customers can now achieve the highest confidence in their in vitro metabolite results, said Dr. Vincent Zurawski, Hepregen CEO. “Partnering with SCIEX has enabled Hepregen to offer researchers the most advanced and predictive hepatic metabolite analysis system in the industry.”
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Study Debunks Fears of Increased Teen Suicide Risk From TamifluNews
Researchers from the University of Illinois at Chicago suggests that the drug oseltamivir - commonly known as Tamiflu - does not cause an increased risk of suicide in pediatric patients.READ MORE